journal
MENU ▼
Read by QxMD icon Read
search

Addiction

journal
https://www.readbyqxmd.com/read/28511286/who-achieves-low-risk-drinking-during-alcohol-treatment-an-analysis-of-patients-in-three-alcohol-clinical-trials
#1
Katie Witkiewitz, Matthew R Pearson, Kevin A Hallgren, Stephen A Maisto, Corey R Roos, Megan Kirouac, Adam D Wilson, Kevin A Montes, Nick Heather
BACKGROUND AND AIMS: There is evidence that low risk drinking is possible during the course of alcohol treatment and can be maintained following treatment. Our aim was to identify characteristics associated with low risk drinking during treatment in a large sample of individuals as they received treatment for alcohol dependence. DESIGN: Integrated analysis of data from the COMBINE study, Project MATCH, and the United Kingdom Alcohol Treatment Trial using repeated measures latent class analysis to identify patterns of drinking and predictors of low risk drinking patterns during treatment...
May 16, 2017: Addiction
https://www.readbyqxmd.com/read/28508582/conceptualizing-behavioural-addiction-in-children-and-adolescents
#2
Anja Kräplin
No abstract text is available yet for this article.
May 15, 2017: Addiction
https://www.readbyqxmd.com/read/28508518/alcohol-marketing-and-youth-drinking-in-asia
#3
LETTER
Heng Jiang, Xiaojun Xiang, Orratai Waleewong, Robin Room
No abstract text is available yet for this article.
May 15, 2017: Addiction
https://www.readbyqxmd.com/read/28504457/electronic-cigarettes-quit-attempts-and-smoking-cessation-a-6-month-follow-up
#4
Anne Pasquereau, Romain Guignard, Raphaël Andler, Viêt Nguyen-Thanh
BACKGROUND AND AIMS: There is conflicting evidence that use of e-cigarettes promotes cessation in regular smokers, but contrasting findings may be due to differing definitions of vaping. The aim was to assess whether regular use of e-cigarettes while smoking is associated with subsequent smoking cessation. DESIGN: Baseline internet survey with outcomes measured at 6-month follow-up. SETTING: All French metropolitan territory. PARTICIPANTS: 2057 smokers aged 15 to 85 years were recruited through an access panel and responded to a 6-month follow-up: 1805 exclusive tobacco smokers and 252 dual users (tobacco plus regular e-cigarette users) at baseline...
May 14, 2017: Addiction
https://www.readbyqxmd.com/read/28498547/the-narcotic-clinic-in-new-orleans-1919-1921
#5
Amund Tallaksen
AIMS: This article traces the history of the narcotic clinic in New Orleans, Louisiana, comparing its merits to a similar clinic in Shreveport. How do the clinics compare, and why did the Shreveport clinic operate for longer than its New Orleans counterpart? METHODS: Qualitative analysis of contemporary medical journals and newspapers, as well as archival materials from the Narcotic Division. In addition, I have utilized the records of Louisiana Governor John M...
May 12, 2017: Addiction
https://www.readbyqxmd.com/read/28498504/varenicline-versus-nicotine-patch-with-brief-advice-for-smokers-with-substance-use-disorders-with-or-without-depression-effects-on-smoking-substance-use-and-depressive-symptoms
#6
Damaris J Rohsenow, Jennifer W Tidey, Rosemarie A Martin, Suzanne M Colby, Robert M Swift, Lorenzo Leggio, Peter M Monti
AIMS: Varenicline was compared with transdermal nicotine (NRT) for smokers with current substance use disorders (SUD) for effects on 3-month smoking abstinence (primary outcome) and, secondarily, on 3 and 6 month abstinence while adjusting for medication adherence, and on additional smoking and substance use outcomes. Moderation by major depressive disorder history (MDD) and adherence were investigated. DESIGN: Double-blind double-placebo controlled randomized design, stratifying by MDD, gender and nicotine dependence, with 3 and 6 months follow up...
May 12, 2017: Addiction
https://www.readbyqxmd.com/read/28498501/ppar-gamma-agonist-pioglitazone-modifies-craving-intensity-and-brain-white-matter-integrity-in-patients-with-primary-cocaine-use-disorder-a-double-blind-randomized-controlled-pilot-trial
#7
Joy M Schmitz, Charles E Green, Khader M Hasan, Jessica Vincent, Robert Suchting, Michael F Weaver, F Gerard Moeller, Ponnada A Narayana, Kathryn A Cunningham, Kelly T Dineley, Scott D Lane
BACKGROUND AND AIMS: Pioglitazone (PIO), a potent agonist of PPAR-gamma, is a promising candidate treatment for cocaine use disorder (CUD). We tested the effects of PIO on targeted mechanisms relevant to CUD: cocaine craving and brain white matter (WM) integrity. Feasibility, medication compliance, and tolerability were evaluated. DESIGN: Two-arm double-blind randomized controlled proof-of-concept pilot trial of PIO or placebo (PLC). SETTING: Single-site outpatient treatment research clinic in Houston, Texas, USA...
May 12, 2017: Addiction
https://www.readbyqxmd.com/read/28498498/impact-of-prescription-drug-monitoring-programs-pdmps-on-opioid-utilization-among-medicare-beneficiaries-in-10-u-s-states
#8
Patience Moyo, Linda Simoni-Wastila, Beth Ann Griffin, Eberechukwu Onukwugha, Donna Harrington, G Caleb Alexander, Francis Palumbo
BACKGROUND AND AIMS: Prescription Drug Monitoring Programs (PDMPs) are a principal strategy used in the USA to address prescription drug abuse. We (1) compared opioid use pre- and post-PDMP implementation and (2) estimated differences of PDMP impact by reason for Medicare eligibility and plan type. DESIGN: Analysis of opioid prescription claims in US states that implemented PDMPs relative to non-PDMP states during 2007-2012. SETTING: Florida, Louisiana, Nebraska, New Jersey, Vermont, Georgia, Wisconsin, Maryland, New Hampshire, and Arkansas, USA...
May 12, 2017: Addiction
https://www.readbyqxmd.com/read/28497595/criteria-for-conceptualizing-behavioural-addiction-should-be-informed-by-the-underlying-behavioural-mechanism
#9
Richard J Tunney, Richard J E James
No abstract text is available yet for this article.
May 11, 2017: Addiction
https://www.readbyqxmd.com/read/28493329/risk-to-heroin-users-of-polydrug-use-of-pregabalin-or-gabapentin
#10
Abigail Lyndon, Suzanne Audrey, Claudia Wells, Erica S Burnell, Suzanne Ingle, Rob Hill, Matthew Hickman, Graeme Henderson
AIM: To examine the risk to heroin users of also using gabapentin or pregabalin (gabapentoids). DESIGN: Multi-disciplinary study: we (a) examined trends in drug-related deaths and gabapentoid prescription data in England and Wales to test for evidence that any increase in deaths mentioning gabapentin or pregabalin is associated with trends in gabapentoid prescribing and is concomitant with opioid use; (b) interviewed people with a history of heroin use about their polydrug use involving gabapentin and pregabalin; and (c) studied the respiratory depressant effects of pregabalin in the absence and presence of morphine in mice to determine whether concomitant exposure increased the degree of respiratory depression observed...
May 10, 2017: Addiction
https://www.readbyqxmd.com/read/28477353/building-the-data-infrastructure-to-evaluate-cannabis-legalization
#11
Beau Kilmer, Rosalie Liccardo Pacula
No abstract text is available yet for this article.
May 5, 2017: Addiction
https://www.readbyqxmd.com/read/28472848/digital-phenotyping-and-the-development-and-delivery-of-health-guidelines-and-behaviour-change-interventions
#12
Andrew L Skinner, Angela S Attwood, Roland Baddeley, Karen Evans-Reeves, Linda Bauld, Marcus R Munafò
No abstract text is available yet for this article.
May 4, 2017: Addiction
https://www.readbyqxmd.com/read/28472847/digital-phenotyping-and-sociological-perspectives-in-a-brave-new-world
#13
Melanie Lovatt, John Holmes
No abstract text is available yet for this article.
May 4, 2017: Addiction
https://www.readbyqxmd.com/read/28449281/effect-of-0-5%C3%A2-mg-vs-1%C3%A2-mg-varenicline-for-smoking-cessation-a-randomized-controlled-trial
#14
Natalia Fouz-Rosón, Teodoro Montemayor-Rubio, Virginia Almadana-Pacheco, Soledad Montserrat-García, Ana Paulina Gómez-Bastero, Concepción Romero-Muñoz, Juan Polo-Padillo
AIMS: Varenicline is used in smoking cessation. The aims of the trial were to test for differences between standard 1 mg and 0.5 mg dose (both twice daily during 8 weeks) in 1) abstinence 2) adherence 3) side effects. DESIGN: Open-label randomized parallel-group controlled trial with 1-year follow-up. All those randomized were included in the final sample using an intention-to-treat (ITT) approach. SETTING: Stop-Smoking Clinic of the Virgen Macarena University Hospital in Seville, Spain...
April 27, 2017: Addiction
https://www.readbyqxmd.com/read/28449191/perceived-harms-and-benefits-of-tobacco-marijuana-and-electronic-vaporizers-among-young-adults-in-colorado-implications-for-health-education-and-research
#15
Lucy Popova, Emily Anne McDonald, Sohrab Sidhu, Rachel Barry, Tracey A Richers Maruyama, Nicolas M Sheon, Pamela M Ling
AIMS: To evaluate how young adults perceive and compare harms and benefits of marijuana and tobacco products in the context of a legal marijuana market in Colorado. DESIGN: Semi-structured qualitative interviews. SETTING: Denver, Colorado, USA. PARTICIPANTS: Thirty-two young adults (18-26 years old) who used tobacco/marijuana/vaporizers. Semi-structured interviews addressed perceived harms and benefits of various tobacco and marijuana products and personal experiences with these products...
April 27, 2017: Addiction
https://www.readbyqxmd.com/read/28431457/precision-medicine-and-pharmacogenetics-what-does-oncology-have-that-addiction-medicine-does-not
#16
Henry R Kranzler, Rachel V Smith, Robert Schnoll, Afaf Moustafa, Emma Greenstreet-Akman
BACKGROUND AND AIMS: Precision, personalized or stratified medicine, which promises to deliver the right treatment to the right patient, is a topic of international interest in both the lay press and the scientific literature. A key aspect of precision medicine is the identification of biomarkers that predict the response to medications (i.e. pharmacogenetics). We examined why, despite the great strides that have been made in biomarker identification in many areas of medicine, only in oncology has there been substantial progress in their clinical implementation...
April 21, 2017: Addiction
https://www.readbyqxmd.com/read/28431456/substance-and-behavioral-addictions-may-share-a-similar-underlying-process-of-dysregulation
#17
Steve Sussman, Dmitri Rozgonjuk, Regina J J M van den Eijnden
No abstract text is available yet for this article.
April 21, 2017: Addiction
https://www.readbyqxmd.com/read/28430388/associations-between-childhood-maltreatment-and-non-medical-use-of-prescription-drugs-among-chinese-adolescents
#18
Lan Guo, Yan Xu, Jianxiong Deng, Xue Gao, Guoliang Huang, Jinghui Huang, Xueqing Deng, Wei-Hong Zhang, Ciyong Lu
AIMS: To test, among Chinese adolescents: (1) whether childhood maltreatment is associated with non-medical use of prescription drugs (NMUPD), (2) whether there are interaction effects of childhood maltreatment and depressive symptoms on NMUPD. DESIGN: A secondary analysis of the cross-sectional data collected from 7(th) and 12(th) graders who were sampled using a multistage, stratified cluster, random sampling method in the 2015 School-based Chinese Adolescents Health Survey (SCAHS)...
April 21, 2017: Addiction
https://www.readbyqxmd.com/read/28430385/significant-reductions-in-alcohol-use-after-hepatitis-c-treatment-results-from-the-french-anrs-co13-hepavih-cohort
#19
Rod Knight, Perrine Roux, Antoine Vilotitch, Fabienne Marcellin, Eric Rosenthal, Laure Esterle, François Boué, David Rey, Lionel Piroth, Stéphanie Dominguez, Philippe Sogni, Dominique Salmon-Ceron, Bruno Spire, Maria Patrizia Carrieri
BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving Peg-interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioral characteristics were collected by yearly self-administered questionnaires...
April 21, 2017: Addiction
https://www.readbyqxmd.com/read/28430384/pharmacokinetics-of-concentrated-naloxone-nasal-spray-over-first-30%C3%A2-minutes-post-dosing-analysis-of-suitability-for-opioid-overdose-reversal
#20
Gill Mundin, Rebecca McDonald, Kevin Smith, Stephen Harris, John Strang
BACKGROUND AND AIMS: Lack of non-injectable naloxone formulations has impeded widespread take-home provision for the prevention of heroin/opioid overdose deaths. For non-injectable formulations that are finally being investigated, rapid onset of action and sufficient bioavailability will be vital. We present analysis of data from a study of concentrated naloxone nasal spray formulations. Our aims are: to assess 1) pharmacokinetic properties and 2) suitability for overdose reversal in terms of naloxone absorption within 30 minutes post-dosing...
April 21, 2017: Addiction
journal
journal
31282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"